Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.69 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.65 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.65 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366392 | 1.00 | BCL2L1 (0.69) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| Hydrochloric Acid SCHEMBL2196804 | 0.98 | BCL2L1 (0.67) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL28162040 | 0.85 | DYRK1A (0.51) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL8958420 | 0.85 | BCL2L1 (0.65) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL31356465 | 0.83 | BCL2L1 (0.74) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL7209477 | 0.83 | BCL2L1 (0.74) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL6321234 | 0.83 | BCL2L1 (0.74) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL28162038 | 0.83 | DYRK1A (0.50) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| Tetrazole SCHEMBL6927480 | 0.82 | SLC9A1 (0.49) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 | |
| SCHEMBL4070224 | 0.82 | BCL2L1 (0.61) | BCL2L1SLC9A1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704828-A2 | INHIBITORS OF JUN N-TERMINAL KINASES (JNK1, JNK2, AND/OR JNK3) AND MITOGEN-ACTIVATED PROTEIN KINASES (MAPK8, MAPK9, AND/OR MAPK10) AND METHODS OF USING SAME | Baylor College of Medicine (US) | 2026-03-11 | — | — | EP | claimed |
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2025-08-19 | — | — | US | claimed |
| WO-2024226609-A2 | INHIBITORS OF JUN N-TERMINAL KINASES (JNK1, JNK2, AND/OR JNK3) AND MITOGEN-ACTIVATED PROTEIN KINASES (MAPK8, MAPK9, AND/OR MAPK10) AND METHODS OF USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2024-10-31 | — | — | WO | claimed |
| US-12005253-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2024-06-11 | — | — | US | claimed |
| EP-4363043-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | Novocure GmbH (CH) | 2024-05-08 | — | — | EP | claimed |
| EP-4365181-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | TiumBio Co., Ltd. (KR) | 2024-05-08 | — | — | EP | claimed |
| CN-117836306-A | Galactose glycoside derivatives as galectin-3 inhibitors | 株式会社蒂奥姆生物 | 2024-04-05 | — | — | CN | claimed |
| CN-114836201-B | Zinc ion-mediated fluorescence sensor and preparation method and application thereof | 哈尔滨理工大学 | 2024-01-26 | — | — | CN | claimed |
| WO-2023275649-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2023-01-05 | — | — | WO | claimed |
| US-20230001193-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | BIOPHARMA CREDIT PLC (GB) | 2023-01-05 | — | — | US | claimed |
| US-5712304-A | MICROBIOCIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-01-27 | — | — | US | claimed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | claimed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | claimed |
| EP-0512349-B1 | Benzothiophene-2-carboxamide-S,S-dioxides | BAYER AG (DE) | 1996-02-14 | — | — | EP | claimed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | claimed |
| EP-0649649-A2 | Colloidal, dispersible formulations of active substances | BAYER AG (DE) | 1995-04-26 | — | — | EP | claimed |
| US-5244893-A | Fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1993-09-14 | — | — | US | claimed |
| EP-0512349-A1 | Benzothiophene-2-carboxamide-S,S-dioxides | BAYER AG (DE) | 1992-11-11 | — | — | EP | claimed |
| US-4761424-A | Enolamides, pharmaceutical compositions and methods for treating inflammation | WARNER-LAMBERT COMPANY (US) | 1988-08-02 | — | — | US | claimed |
| EP-0221345-A1 | Novel enolamides, process for their manufacture and pharmaceutical compositions thereof with an activity as modulators of the arachidonic acid cascade | WARNER-LAMBERT COMPANY (US) | 1987-05-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391680-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | BCL2L1 2334/4885SLC9A1 91/4885HDAC3 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.